{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-23-000146","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.996714+00:00","generated_at":"2026-06-09T01:21:16.502262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance","bullets":["Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.","Non-GAAP net income $749k ($0.02/share) vs ($1.9M) loss a year ago; adjusted EBITDA up 34% to $13.9M.","Aortic stent graft revenue surged 30% GAAP (22% constant currency); On-X revenue up 14% (13% cc).","FY2023 revenue guidance raised to $349-351M (prior $342-350M); constant currency growth now 11-12%.","Expects 2023 adjusted EBITDA >$52M (+25% YoY); PERSEVERE trial enrollment nearing completion (90 of 93)."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-23-000146","json":"https://secwatch.observer/filing/0000784199-23-000146.json","markdown":"https://secwatch.observer/filing/0000784199-23-000146.md","text":"https://secwatch.observer/filing/0000784199-23-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000146/0000784199-23-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000146/aort-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:21:16.502262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0bc036ba3f80955ef9b274cc25eaa2cf4575910","claim":"ARTIVION, INC. reported the third quarter ended September 30, 2023 results: revenue $87.9 million, net income ($9.8) million, EPS ($0.24) per fully diluted common share. Guidance raised.","evidence_excerpt":"Officer investors@artivion.com Phone: 770-419-3355 Artivion Reports Third Quarter 2023 Financial Results Third Quarter and Recent Business Highlights: • Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 12% on a non-GAAP constant currency basis • Net loss was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000146/0000784199-23-000146-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$87.9 million"},{"label":"Net income","value":"($9.8) million"},{"label":"EPS","value":"($0.24) per fully diluted common share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}